

#### 26 Tel: +86 0571 8609 0073

- 27
- 28 **Keywords:** Carbapenem-resistant *Acinetobacter baumannii*, Intensive Care, Genomic
- 29 Epidemiology, Infection Prevention and Control, Antimicrobial Resistance.

## 30 **Abstract**

31 Carbapenem-resistant *Acinetobacter baumannii* (CRAB) is a persistent nosocomial pathogen 32 that poses a significant threat to global public health. A three-month cross-sectional 33 observational study was conducted in a 28-bed ICU in Hangzhou, China. The same ICU was 34 sampled for the same duration and with a similar methodology in 2019, 20 months prior to 35 the outset of this study. Following COVID-19-associated delays, a series of IPC measures 36 targeting patients, staff and the ICU environment were implemented for 8 months prior to and 37 throughout this study. A total of 5,341 samples were collected from the ICU environment (n 38 = 4450) and patients (n = 891). *A. baumannii* isolates were obtained from 9·5% of these 39 samples (n = 505). Most *A. baumannii* isolated in this ICU were CRAB (419/518; 80·9%). 40 Fewer CRAB were isolated here (407 from 363 sampling occasions) than in 2019 (502 from 41 336 sampling occasions). However,  $MIC<sub>50</sub>/MIC<sub>90</sub>$  values for imipenem increased from 32/64 42 mg/L in the 2019 study to 64/128 mg/L here. This was accompanied by the proportion of 43 global clone 2 (GC2) isolates falling from 99·5% in 2019 to 50·8% (213/419) in 2021. The 44 phylogenetic diversity of GC2 increased, apparently driven by regular introductions of 45 distinct clusters in association with patients. The remaining CRAB (40·2%; 206/419) were a 46 highly clonal population of ST164, which appears to have persisted in the ICU since an 47 introduction in mid-2020. We found clusters of GC2 and ST164 isolates with identical core 48 genomes in different room or bed unit environments, and in multiple patients, indicative of 49 transmission in the ICU.

50 Changes to IPC procedures in this ICU were associated with a reduction in the total 51 prevalence of CRAB, and in the number of CRAB isolated from clinical specimens. At the 52 phenotypic level, the CRAB population exhibited increased resistance to carbapenems, and 53 this may be the result of increased antibiotic prescribing over the COVID-19 period. The 54 increased diversity of this CRAB population appears to have been the result of repeated

55 introductions to the ICU with patients, which have continued despite interventions.

## 56 **Introduction**

57

58 *Acinetobacter baumannii* is a Gram-negative bacterial pathogen that causes ventilator-59 associated pneumonia and bloodstream infections in critically ill hospital patients globally.<sup>1,2</sup> 60 The morbidity and mortality associated with *A. baumannii* infections are exacerbated by its 61 extensive resistance to antibiotics. Carbapenem-resistant *A. baumannii* (CRAB) are often 62 only sensitive to tigecycline and polymyxins,  $3$  and can persist in hospital environments and 63 patients for extended periods.<sup>1</sup> Resolving CRAB outbreaks can require modifications to 64 practice and infrastructure that impose significant clinical, logistical, and financial costs.<sup>4</sup> In 65 2018, the World Health Organisation declared CRAB a priority organism for which novel 66 therapeutics are urgently required.<sup>5</sup>

67

68 Given the limited options for antimicrobial chemotherapy, infection prevention and control (IPC) strategies must play a substantial role in limiting the impact of CRAB in hospitals.<sup>6</sup> 70 Effective genomic surveillance has the capacity to inform IPC approaches by defining 71 outbreaks and identifying sources and pathways for bacterial transmission. Recent hospital 72 studies have demonstrated the utility of whole-genome sequencing (WGS) for high-resolution 73 characterisation of *A. baumannii* outbreaks or persistent populations.<sup>6–9</sup> The crucial need to 74 develop a thorough understanding of the longer-term persistence, transmission and evolution 75 of CRAB populations in nosocomial environments provided the motivation for undertaking 76 this study.

77

78 In August-October 2019, we conducted a 13-week genomic surveillance study of CRAB in a 28-bed intensive care unit (ICU) located in Hangzhou, China.<sup>10</sup> 79 We found that the ICU

80 CRAB population was dominated by representatives of global clone 2 (GC2), which is one 81 of two clones that account for the majority of CRAB globally.<sup>3</sup> Consistent with global 82 reports, carbapenem resistance in this GC2 population was conferred by the *bla*<sub>OXA-23</sub> 83 carbapenemase gene, which was present in composite transposons Tn*2006* or Tn*2009* 84 inserted at several different chromosomal sites.<sup>10</sup> Comparative analyses revealed that the GC2 85 population in this ICU was phylogenetically diverse, and the diversity appeared to have been 86 shaped by independent introductions of multiple distinct GC2 clusters to the ICU. We 87 detected putative CRAB transmission events between bed units and rooms within the ICU, 88 and the spatiotemporal co-location of diverse CRAB clusters facilitated three horizontal gene 89 transfer events over the course of the study.<sup>10</sup>

90

91 Informed by that first study, we planned to implement a set of IPC interventions, then 92 perform a follow-up study to evaluate their effectiveness in reducing the prevalence of CRAB 93 in the ICU. However, ICU operations were interrupted by the outbreak of COVID-19 in early 94 2020, and access to the ICU was restricted. Consequently, the implementation of planned 95 CRAB-focused interventions was delayed until September 2020. Once introduced, the suite 96 of interventions targeted ICU patients, the ICU environment (including equipment and sinks), 97 and ICU staff (Table S1). Full access to the ICU was restored in late November 2020, 98 enabling us to conduct a second high-resolution genomic surveillance study, with a 99 methodology identical to that of our pre-COVID-19 pandemic study, in May-July 2021.

100

101 Here we describe the follow-up cross-sectional observational study of *A. baumannii* in this 102 Hangzhou ICU. Over a 13-week period, we applied a deep-sampling approach to ICU 103 patients and the ICU environment. All *A. baumannii* isolates were whole-genome sequenced. 104 The structure and dynamics of this population were compared to those from our original

105 study to evaluate the population's longer-term development, and its response to IPC 106 interventions.

107

## 108 **Methods**

109

#### 110 **Consent and research ethics**

111 Ethical approval and informed consent were obtained by the Sir Run Run Shaw Hospital 112 (SRRSH) Zhejiang University local ethics committee (approval number 20190802-1). This 113 work was part of a study registered as a clinical trial with ClinicalTrials.gov (NCT04310722).

114

## 115 **IPC interventions implemented before this study**

116 A bundled set of interventions that aimed to address the abundance of CRAB in this ICU 117 were implemented 8 months prior to the outset of this study. The interventions included 118 changes to daily practice in the ICU, alongside raising staff awareness around the issue. The 119 interventions are listed in Table S1. Briefly, patient care was modified by introducing "water-120 free" cleaning methods and by installing disinfection devices for liquid waste. ICU sinks 121 ceased operation. Environmental cleaning was performed more regularly, with particular 122 attention paid to end-of-stay cleaning procedures and communal surfaces such as keyboards 123 used routinely by ICU staff. Education for staff was enhanced, and enforcement of hand 124 hygiene practices was targeted through compliance monitoring and the introduction of a 125 compliance management system.

126

#### 127 **Study design and sample collection**

128 This cross-sectional observational study was conducted in a 28-bed ICU in SRRSH, 129 Hangzhou, China from May to July 2021. A map of the ICU is presented in Figure S1. Unless

130 sampling was perceived to be medically detrimental, ICU patient sampling was planned for 131 the beginning of the study or on admission to the ward and weekly thereafter. Patient samples 132 were routinely collected from oral and rectal swabs, and from nasogastric, nasojejunal, 133 endotracheal, or tracheostomy tube swabs when present. Clinical samples were obtained from 134 patients as part of normal medical practice, and all *A. baumannii* obtained from clinical 135 samples over the study period were retained. Equipment, sinks and other surfaces within 136 patient rooms were swabbed weekly. Equipment, surfaces, and sinks in communal areas 137 outside patient rooms were sampled monthly.

138

## 139 **Sample processing and DNA sequencing**

140 Environmental surfaces (approximately 10 x 10 cm) were swabbed with sterile swabs 141 (COPAN, Italy) pre-moistened with 2 mL TSB supplemented with 0·1% sodium thiosulfate 142 (Sangon Biotech, China). The swabs were immediately placed into 14-mL sterile tubes 143 containing 2 mL TSB with 0·1% sodium thiosulfate then incubated for 24 hours at 37°C. 144 After culture, 20 µL overnight bacteria were streaked onto Acinetobacter CHROMagar plates 145 (CHROMagar, Paris, France) followed by overnight incubation at 37°C.

146

147 For patient samples, rectal swabs containing Cary-Blair Transport Medium (Gongdong, 148 Taizhou, China) were used and other swabs were moistened using 0·9% saline before 149 sampling. These swabs were plated directly onto Acinetobacter CHROMagar plates and 150 incubated at 37°C for 24 hours. Based on red colour and morphology, a single, isolated 151 colony of presumptive *A. baumannii* was selected and streaked onto a Mueller-Hinton (MH) 152 agar plate (Oxoid, Hampshire, UK), then incubated again at 37°C for 24 hours. A single, 153 isolated colony from the MH plate was selected and stored for downstream analyses.

154

155 Species identification was confirmed using Matrix-assisted laser desorption ionization-time 156 of flight mass spectrometry (MALDI-TOF MS) (bioMérieux, France) and 16S rRNA gene 157 sequencing using the primers 27F-5'- AGAGTTTGATCCTGGCTCAG -3' and 1492R-5'- 158 GGTTACCTTGTTACGACTT -3'.

159

#### 160 **Antimicrobial susceptibility profiling**

161 Minimum inhibitory concentrations (MICs) of meropenem, imipenem, polymixin B, 162 tigecycline, cefoperazone/sulbactam (1:1), cefoperazone/sulbactam (2:1), sulbactam, 163 amikacin and ciprofloxacin were measured using the broth microdilution method of plate for 164 "Susceptibility testing of non-fastidious Gram Negative isolates". Results were interpreted 165 according to the Clinical and Laboratory Standards Institute 2021 guidelines and European 166 Committee on Antimicrobial Susceptibility Testing (EUCAST) 2023 breakpoint tables 167 (http://www.eucast.org/clinical\_breakpoints/) for polymyxin B (S: ≤2 mg/L, R: >2 mg/L).

168 Tigecycline results were interpreted based on Food and Drug Administration (FDA) 169 guidelines. *Escherichia coli* ATCC 25922 was used as the quality control strain.

170

#### 171 **Illumina sequencing**

172 Collected isolates were subjected to Illumina sequencing. One colony of each isolate was 173 cultured in 2 mL Mueller-Hinton broth (Oxoid, UK) for 24 hours at 37°C. Cell pellets were 174 harvested and DNA was isolated using the Qiagen Mini Kit (Qiagen, Germany). The quality 175 and quantity of DNA were assessed using a NanoDrop 2000 (Thermo Scientific, USA) and 176 Qubit 4.0 fluorometer (Invitrogen, USA).

177

178 Libraries were prepared using the TruePrepTM DNA Library Prep Kit V2 (Vazyme) 179 according to the manufacturer's protocol. Individual libraries were assessed on the QIAxcel

180 Advanced Automatic nucleic acid analyzer using a high-resolution gel cartridge (Qiagen, 181 Germany), and then were quantified by qPCR using the use of KAPA SYBR FAST qPCR 182 Kits Kapa KK4610 (KAPA Biosystem, Wilmington, MA, U.S.A.). Paired-end sequencing 183 (2×150-bp reads) was performed on the Illumina HiSeq X Ten platform (Illumina Inc., San 184 Diego, CA, USA).

185

## 186 **Oxford Nanopore sequencing**

187 Long-read sequencing was performed for 60 isolates chosen after Illumina sequencing on the 188 basis of phylogenetic, resistance gene and plasmid diversity. Genomic DNA was extracted 189 using the Gentra® Puregene® Yeast/Bact. Kit (Qiagen, Germany) according to the 190 manufacturer's protocol with minor modifications. Briefly, cell pellets were harvested in a 191 sterile 15 mL falcon tube from 5mL overnight culture. Each pellet was resuspended in 500 192 µL Lysis Buffer Solution, transferred to a Phase Lock tube and incubated at 37°C for 30 193 minutes. Cell lysates were treated with 2 µL RNase A (100 mg/mL, Qiagen, Germany), 194 gently mixed by flicking the tube and incubated at 37<sup>o</sup>C for 30 minutes. The cell lysate was 195 further treated with 3 µL Proteinase K (Qiagen, Germany), mixed by gentle inversion and 196 incubated at 50°C for 90 minutes. The suspension was mixed with 500 µL 197 phenol:chloroform:isoamyl alcohol (25:24:1) by inversion and centrifuged at 20,000 rcf for 198 10 minutes. The supernatant was collected and DNA was purified using AMPure XP beads 199 (Beckman Coulter™) with minor modifications to the manufacturer's protocol: 70% ethanol 200 was used for washing the DNA on the beads before incubation at 37°C for 5 min to dry off 201 residual ethanol. The DNA was resuspended in  $150 \mu L$  of nuclease-free water. The quality 202 and quantity of DNA were assessed as described above.

203

204 Oxford Nanopore sequencing libraries were prepared using the SQU-LSK109 Ligation 205 Sequencing Kit (Oxford Nanopore Technologies, UK) in conjunction with the PCR-Free 206 ONT EXP-NBD104 Native Barcode Expansion Kit (Oxford Nanopore Technologies, UK) 207 according to the native barcoding genomic DNA protocol. DNA was processed without the 208 optional shearing steps to select for long reads. After quantification of the individual libraries 209 by Qubit and normalisation of library concentrations, the library was sequenced on the 210 GridION X5 platform (Oxford Nanopore Technologies, UK).

211 Raw Illumina and Minion sequence data for all isolates is available via National Center for

212 Biotechnology Information under BioProject accession PRJNA1034534.

213

#### 214 **Bioinformatic analyses**

215 Sequence reads were trimmed, assembled and assessed for quality. MLST 216 (https://github.com/tseemann/mlst) was used to determine multi-locus sequence types with 217 the Pasteur and Oxford typing schemes.<sup>11,12</sup> Typing of capsular polysaccharide (KL) and 218 lipooligosaccharide outer core  $(OCL)$  synthesis loci was conducted with Kaptive.<sup>13</sup> 219 AMRFinder was used to identify antimicrobial resistance genes.<sup>14</sup> Plasmid replicons were 220 typed using the Hamidian lab typing scheme.<sup>15</sup>

221

222 Snippy v4.4.5 (https://github.com/tseemann/snippy) was used to align Illumina reads against 223 a corresponding reference hybrid assembly and generate a core genome alignment. 224 Polymorphic sites were extracted with Gubbins v2.4.0 excluding those that were predicted to 225 occur via recombination.<sup>16</sup> Phylogenies were constructed from these polymorphic sites using 226 IQtree v2.0.3. Divergence dating was undertaken with the least-squares method implemented 227 by IQTree v2.0.3, using the previously generated tree, Gubbins fasta file, and a GTR+G 228 model.<sup>17,18</sup> SNP-distances were calculated from the Gubbins-filtered polymorphic sites file

229 using SNP-dists 0.6.3 (https://github.com/tseemann/snp-dists).

230

231 **Results**

232

#### 233 *A. baumannii* **infections were rare despite high abundance in patients and bed units**

234 A total of 131 patients (79 male; 52 female; median age 68 years; interquartile range [IQR] = 235 55·5 – 77·5) were sampled over the three-month study period (Table S2). The median length 236 of patient stay, from admission to discharge or the end of the study, was 10 days (IQR:  $5 -$ 237 21·5 days). Most patients (53·4%) were in the ICU for ≤10 days, but 17·1% were present for 238 > 31 days. Samples were taken each Tuesday, and patients were screened within the first 48 239 hours after admission when possible. "Bed units", defined as the environmental sites of each 240 bed and its associated equipment, were sampled on 363/364 (99·7%) planned sampling 241 occasions, as one patient was undergoing bedside surgery on a single planned sampling 242 occasion. Patients were sampled on 303/346 (87·6%) planned occasions.

243

244 A total of 5,341 samples were collected from patients and environmental sites. *A. baumannii* 245 was isolated from 505 samples: 382/4450 (8·6%) environmental samples and 123/891 246 (13·8%) patient samples. Bed units yielded more environmental isolates (374/4317, 8·7%) 247 than communal areas outside bed units (8/133 samples, 6·0 %). Within bed units, ventilators 248 (56/281 samples, 19·9%) and ventilator shelves (40/275 samples, 14·6%) yielded the most *A.*  249 *baumannii*. Of the 131 patients screened, 41·2% (54/131) were *A. baumannii*-positive on at 250 least one sampling occasion, with most of the positive samples originating from nasogastric 251 tube (33/174, 19·0%) or oral (40/220, 18.2%) swabs. A set of 13 isolates obtained from 252 diagnostic clinical specimens were collected from 10 patients over the study period; one from 253 an abdominal excision exudate and 12 from sputum.

254

#### 255 **Most ICU** *A. baumannii* **were carbapenem-resistant**

256 Over the study period, 19·1% (25/131) of ICU patients were treated with the carbapenems 257 imipenem, meropenem, or ertapenem. MIC testing of all 520 *A. baumannii* in this collection 258 revealed that the rates of resistance to both imipenem and meropenem were 80·9% (419/518) 259 (Figure S2). A larger proportion of patient isolates (116/123; 94.3%) were CRAB than 260 environmental isolates (303/382; 79.3%). The β-lactam/β-lactamase inhibitor combinations 261 cefoperazone/sulbactam and piperacillin/tazobactam were administered to 14·5% (19/131) 262 and 40·5% (53/131) of patients, respectively. The resistance rates to these combinations were 263 80·3% (416/518) for cefoperazone-sulbactam (1:1) and 81·1% (420/518) for cefoperazone-264 sulbactam (2:1). Resistance rates to sulbactam alone, ciprofloxacin, and amikacin were 265 80·9% (419/518), 80·9% (419/518), and 23·0% (119/518), respectively. All isolates were 266 sensitive to colistin and to tigecycline.

267

268 To quantify levels of carbapenem resistance in the CRAB populations from before and after 269 the intervention period, we compared the imipenem MICs that would be sufficient to inhibit 270 50% (MIC<sub>50</sub>) and 90% (MIC<sub>90</sub>) of all isolates in each collection. For the 419 CRAB isolated 271 in this study, the MIC<sub>50</sub> and MIC<sub>90</sub> to imipenem were 64 mg/L and 128 mg/L, respectively. 272 The imipenem  $MIC<sub>50</sub>/MIC<sub>90</sub>$  values for the 551 CRAB isolated in our first study were 32 273 mg/L and 64 mg/L, respectively. This data reflects an increase in carbapenem resistance 274 levels in this ICU between 2019 and 2021. However, total sensitivity to colistin and 275 tigecycline remained consistent across study periods.

276

## 277 **Whole-genome sequencing revealed shifts in the circulating CRAB population**

278 All *A. baumannii* isolates were whole-genome sequenced (Table S3). Genome sequence data 279 revealed that the population included representatives of 35 different sequence types according 280 to the Pasteur MLST scheme (Figure 1A). Most of the diversity was seen amongst the 281 carbapenem-sensitive population, which included isolates from 33 different STs, 20 of which 282 were represented by a single isolate each. Only three of these STs were represented by ten or 283 more isolates: ST240, ST40, and ST221. The carbapenem-resistant population was comprised 284 of just two sequence types: ST2/GC2 (213 isolates; 50·8%) and ST164 (206 isolates; 49·2%). 285 The presence of ST164, accounting for approximately half of the CRAB isolates in this study, 286 represents a major shift from 2019, where the CRAB population was dominated by GC2 287 (548/551; 99·5%) (Figure 1A). ST164 isolates were obtained from clinical specimens in this 288 ICU earlier in 2021,<sup>19</sup> and this ST has recently been declared an international clone (IC11), 289 with reports of human infections in Europe, Asia, Africa and the Middle East.<sup>20</sup> Imipenem 290 MIC<sub>50</sub>/MIC<sub>90</sub> values for the 206 ST164 isolates were 128/128 mg/L, and 32/64 mg/L for the 291 213 GC isolates, indicating that the appearance of ST164 was responsible for the overall 292 increase in carbapenem resistance between studies.

293

294 GC2 and ST164 were isolated throughout the study period and across the ICU (Figure 1). On 295 37/364 (10·2%) sampling occasions, GC2 and ST164 were isolated from the same bed unit. 296 Despite their near-even prevalence in the ICU environment and patients, GC2 strikingly 297 accounted for 12/13 (92·3%) clinical isolates obtained over the study period, with the 298 remaining sputum isolate belonging to ST164. In contrast to GC2 and ST164, carbapenem-299 sensitive (CSAB) STs appeared sporadically over the course of the study and were generally 300 localised to a single room, patient or time point (Figure S3).

301

#### 302 **The GC2 population shifted significantly between studies through the introduction of**

#### 303 **multiple discrete sub-clusters**

304 Consistent with our first study, carbapenem-resistance in GC2 CRAB isolates was conferred 305 by the carbapenemase gene  $bla_{\text{OXA-23}}$ . To determine the genomic contexts of these  $bla_{\text{OXA-23}}$ 306 genes, we examined 19 hybrid-assembled complete GC2 genomes, and screened the 307 collection of 213 GC2 draft genomes with signature sequences indicative of the Tn*2006* or 308 The *Th*<sup>2009</sup> insertions identified in our first study.<sup>10</sup> This revealed that the chromosomal positions 309 encountered in the first study accounted for  $bla_{\text{OXA-23}}$  carriage in all GC2 isolates collected 310 here (Figure 2A; Table S3). Additionally, one hybrid-assembled genome (DETAB-E2110) 311 contained two copies of Tn*2006*, with the second copy found in the 13,545 bp plasmid 312 pDETAB10::Tn*2006* (Figure S4). pDETAB10::Tn*2006* was generated by the insertion of 313 Tn*2006* into the backbone of the 8,731 bp R2-T1 type plasmid pDETAB10, which was 314 present in 75/547 (13·7%) GC2 isolates in our first study and 175/213 (82·2%) GC2 isolates 315 here. Screening this collection with the signatures of this insertion revealed that 316 pDETAB10::Tn*2006* was not present in any other isolates. DETAB-E2110 had MIC values of 317 128 mg/L and >128 mg/L for imipenem and meropenem, which were the equal-highest 318 observed in this collection.

319

320 Although the GC2 isolates collected here shared Tn*2006*/Tn*2009* insertions with the GC2 321 clusters examined in our previous study, chromosomal segments that contain transposons can 322 be exchanged by homologous recombination between distinct *A. baumannii* strains,<sup>21</sup> so we 323 sought phylogenetic evidence to assess cluster persistence in this ICU. To determine whether 324 the GC2 population observed in this study was derived from that present in 2019, we 325 constructed a phylogeny from the GC2 genomes obtained here, along with representative 326 genomes for each of the 17 GC2 clusters identified in our first study (Figure 2A). The

327 phylogeny featured three large clusters that included 49, 72 and 92 GC2 genomes from this 328 study. Representatives of 16 GC2 clusters from the 2019 study were confined to the diverse 329 central cluster, with a single representative present in one of the two more clonal clusters, 330 cluster 24 (C24) (Figure 2A). Within the diverse central cluster, representatives from study 1 331 were largely distinct from isolates collected here, with the exception of C16, which differed 332 from isolate DETAB-P494 by just one core-gene SNP (cgSNP). Overall the GC2 population 333 was more diverse in 2021 than it was in 2019, which is consistent with frequent and ongoing 334 introductions of distinct GC2 clusters to the ICU. Further supporting this, some GC2 clusters 335 appeared briefly in the ICU, and were present for no more than three sampling weeks (Figure 336 2B). These will be referred to as transient GC2 clusters.

337

338 To detect putative patient-associated introductions to the ICU over the course of this study, 339 we identified instances where, apart from in week 1, the first isolates of transient GC2 340 clusters appeared in patient samples. We found six such instances, involving six different 341 clusters (Figure 2C). Within transient clusters, isolates differed by 0-4 cgSNPs. C22 was 342 represented by a single patient isolate, but isolates of the other five clusters were found in two 343 or more different environments each. These included the bed units occupied by the patients 344 that initially carried the clusters, and either bed units within the same rooms (C18, C19, C21), 345 bed units in different rooms (C23), or a communal cleaning cart (C20) (Figure 2C). C19 and 346 C21 were carried by two patients each, and the second patient that each cluster was isolated 347 from most parsimoniously acquired C19/C21 from their contaminated room environments. 348 All six transient GC2 clusters that first appeared in patient samples disappeared from the ICU 349 following the departure of the last patient that carried them (Figure 2C).

350

351 The largest GC2 clusters, C24 and C25, were present in most (10/13 for C24) or all (13/13 352 for C25) study weeks (Figure 2B). The largest cluster, C25, only contained genomes from 353 this study, all of which differed from one another by 0-6 cgSNPs (Table S4). Isolates in C24 354 differed from one another by 0-11 cgSNPs, and from the study 1 representative C2 genome 355 by 5-10 cgSNPs (Table S4). As representatives of C24 and C25 were already present in the 356 first week of this study (Figure 2B), we did not capture their introductions to the ICU, so 357 cannot determine whether they were introduced in single or multiple events. However, the 358 presence of sub-clusters of C24 and C25, containing isolates that do not differ at the cgSNP 359 level (0 cgSNPs) but were found in multiple bed units or rooms, is evidence for the ongoing 360 transmission of C24 and C25 within the ICU.

361

#### 362 **ST164: A dominant new strain type recently introduced but fully established in the ICU**

363 ST164 was not detected in this ICU in our first study. It was therefore important to establish 364 whether this lineage had been introduced recently or had persisted in the ICU for an extended 365 period. To assess their structural diversity, eight ST164 isolates were hybrid-sequenced to 366 generate complete genomes. All eight complete genomes consisted of a 3.9 Mbp 367 chromosome and five plasmids, pDETEC17 to pDETEC21, that ranged from 12,790 bp to 368 2,309 bp (Figure 3A). Screening the entire collection of 206 ST164 short-read assemblies 369 revealed that the five plasmids were present in almost all ST164 isolates (pDETAB19 370 195/206; pDETAB17 201/206; others 206/206).

371

372 All ST164 genomes contained five acquired antibiotic resistance genes (ARGs). Four of these 373 encoded beta-lactamases:  $bla_{NDM-1}$ ,  $bla_{OXA-23}$ ,  $bla_{CARB-16}$  and  $ampC$  (also called  $bla_{ADC}$ ). In the 374 complete ST164 genomes, all ARGs were located in the chromosome (Figure 3A). The 375 *bla*<sub>NDM-1</sub> gene was in the complex transposon  $Tn6924$ <sup>22</sup> along with the bleomycin resistance

376 gene *ble*<sub>MBL</sub> and the aminoglycoside resistance gene *aphA6*. The remaining beta-lactamase 377 genes were in four ISAbal composite transposons: *bla*<sub>OXA-23</sub> in two copies of Tn2006, *ampC* 378 in Tn*6168*, and *bla*CARB-16 in a novel transposon named Tn*7735* (Figure 3A). Screening draft 379 genomes with the junction sequences associated with all five ARG-containing insertions 380 revealed that they were totally conserved across this ST164 population.

381

382 The near-total conservation of mobile genetic elements and chromosomal insertion sites 383 suggested that the ST164 population in this ICU was highly clonal. To confirm this, we 384 determined cgSNPs between all isolates in this collection and found that they ranged from 0- 385 21. We did not find evidence for the introduction of ST164 clusters with patients over the 386 course of this study, and we were aware that the same ST had been isolated from a sputum 387 specimen collected in this ICU in January  $2021$ ,<sup>19</sup> four months prior to this study. We 388 therefore used the genome of that clinical isolate, DETAB-R21, as a reference for a time-389 dated phylogeny for the genomes generated here (Figure 3B). The time-dated phylogeny was 390 consistent with this ST164 population having diversified from an initial introduction to the 391 ICU in mid-2020. The two deepest branches in this phylogeny had estimated dates of 392 divergence from a common ancestor in April 2020, giving rise to clusters 164-A and 164-B 393 (Figure 3B). DETAB-R21 clustered with 164-B. Both 164-A and 164-B were present in the 394 first and last weeks of this study, but were not present in every intervening week, with no 395 164-A isolates in week 11 and no 164-B in weeks 3 and 12 (Figure 4). Clusters 164-C 396 (present in weeks 5-13) and 164-D (weeks 2, 5-10), emerged from 164-A and 164-B, 397 respectively (Figure 3B), and were not present in the ICU at the outset of the study (Figure 398 4). Notably, the first isolates of 164-C and 164-D were derived from environmental samples 399 rather than patient samples, consistent with their emergence from an existing ICU population 400 rather than from patient-associated introductions.

401



# 413 **Persistence of CRAB in the ICU results in clinically-relevant CRAB acquisition by**  414 **patients**

415 Using the phylogenetic evidence described above, we sought to determine the derivation of 416 each of the 13 CRAB clinical isolates collected over the course of this study, and therefore to 417 identify the routes through which they might have been acquired by these 10 patients over the 418 study period. Most (12/13) of the clinical isolates were GC2, and amongst these 10 were C25, 419 one was C24, and one was C21. The remaining clinical isolate was ST164-D. Representatives 420 of all four of these clusters were present in multiple patient and environmental samples prior 421 to their appearance in clinical samples, but to avoid any ambiguity associated with small 422 numbers of cgSNPs  $(\leq 4)$ , we focused on comparing identical  $(0 \text{ cgSNP})$  isolates when 423 describing clinically-relevant CRAB acquisition in the ICU.

424

425 The GC2 C21 cluster was clearly introduced to the ICU by patient 200 (P200) (see above,

426 Figure 2), so its presence in a P200 clinical sample is indicative of acquisition elsewhere 427 before the development of clinically-relevant symptoms requiring sputum sample collection 428 in this ICU. The GC2 C24 isolate obtained from P172 was identical to isolates obtained from 429 P172's first screening samples on arrival to the ICU, which might suggest that they carried 430 C24 on arrival. However, because C24 was circulating in the ICU (see above), and identical 431 isolates had been obtained from other patients and the ICU environment prior to the 432 admission of P172, it is also possible that P172 acquired C24 in the ICU before their first 433 screening samples were taken.

434

435 In the remaining eight cases, patients had been CRAB-negative at one or more sampling 436 points prior to the development of symptoms that necessitated clinical sample collection. It 437 therefore seems most parsimonious that all of these patients acquired CRAB in the ICU, and 438 in three of these cases isolates identical to the clinical isolates had previously been isolated 439 from the ICU environment. In the remaining five cases, the clinical isolates were not identical 440 to any other isolates in the collection, but were highly similar to multiple other isolates, 441 differing by ≤4 cgSNPs. We conclude that acquisition in the ICU was responsible for the 442 majority (9 or 10/10) of CRAB found in clinically-relevant patient samples over the course of 443 this study.

444

445

# 446 **Discussion**

447

448 This follow-up observational study has allowed us to assess the influence of bundled IPC 449 interventions on an endemic ICU CRAB population, in a region where CRAB prevalence is 450 highest globally.<sup>23</sup> The nature of bundled intervention strategies complicates assessments of

451 the impacts of individual IPC measures, and this was further complicated here by the time 452 that passed between studies, as well as by the changes to ICU access and practice associated 453 with responses to COVID-19. However, the unique timing of our studies either side of the 454 emergence of COVID-19 also afforded us an opportunity to determine the joint impacts of 455 the intervention strategies as well as the COVID-19 pandemic on antimicrobial resistance in 456 *A. baumannii*.

458 The early and middle periods of the COVID-19 pandemic were associated with increased 459 rates of antibiotic prescribing in China,  $24$  which may have augmented resistance levels in 460 nosocomial bacterial populations. Increased prescription of ß-lactam antibiotics (including 461 carbapenems) and tigecycline, which have been reported across multiple studies. $24$  are 462 particularly concerning in the context of *A. baumannii*. The phenotype-agnostic approach to 463 sampling in this study allowed us to determine that the majority (80·8%) of *A. baumannii* in 464 this ICU were CRAB. We observed an increase in the magnitude of carbapenem resistance in 465 this ICU, with  $MIC<sub>50</sub>/MIC<sub>90</sub>$  values doubling between our 2019 and 2021 studies. The 466 increase in carbapenem resistance levels was driven by the emergence of ST164, which co-467 produced NDM-1 and OXA-23 carbapenemases. Despite the increase in carbapenem 468 resistance, all isolates obtained in 2021 remained sensitive to colistin and tigecycline, though 469 monitoring CRAB populations for resistance to these last-resort antibiotics should remain a 470 high priority.

471

472 Following IPC interventions, we observed a decrease in the numbers of CRAB isolated from 473 patients and from the ICU environment, and saw a reduction in both the total number of 474 clinical isolates (from 19 in 2019 to 13 in 2021) and the number of patients from which 475 clinical isolates were obtained: 12/140 patients (8·6%) in 2019, and 10/131 patients (7·6%) in

<sup>457</sup> 

476 2021. However, IPC practices remained imperfect, with multiple examples of GC2 CRAB 477 clusters being imported to the ICU before spreading to different bed units or rooms and being 478 acquired by patients, highlighting the significant challenges associated with prevention of 479 CRAB transmission in hospital wards once it has colonised the hospital environment. By 480 using a highly-stringent 0-cgSNP cut-off when assessing putative transmission events over 481 the course of this study, we have unambiguously implicated environmental persistence in the 482 acquisition of CRAB by ICU patients and ultimately the development of nosocomial 483 infections. New data presented here adds to our previous findings that suggested GC2 clusters 484 were being imported to the ICU regularly from external sources. We hypothesise that other 485 wards within this hospital, as well as patients transferred from other hospitals, serve as a 486 source for incoming CRAB strains. If this is the case, hospital-wide IPC measures or highly 487 stringent screening and isolation of CRAB-positive patients prior to ICU admission will be 488 required to ultimately address CRAB imports.

489

490 A striking finding here was the reduction in prevalence of GC2 amongst CRAB isolates, 491 falling from 99·5% in 2019 to 50·8% in 2021. The remainder of the 2021 CRAB population 492 was comprised of a highly-clonal set of ST164 isolates that appear to have been diversifying 493 *in situ* since mid-2020. This study has therefore added further context to the recent 494 recognition of the emergence of ST164 as an international *A. baumannii* clone,<sup>20</sup> with our 495 data specifically highlighting this clone's capacity to establish itself and persist in an ICU 496 environment, even in direct competition with clusters of the highly successful GC2. While 497 ST164 caused fewer infections than GC2 over this study period, its presence in one clinical 498 specimen, and in clinical specimens collected previously in this ICU and elsewhere,  $19,20$  along 499 with its high carbapenem resistance levels, suggest that it is a lineage that requires 500 surveillance and further characterisation.

501

502 The increase in CRAB diversity between 2019 and 2021, including the appearance of ST164 503 and the diversification of GC2, was likely a product of regular imports to the ICU over an 504 approximately 20-month period. However, it would be interesting to determine whether IPC 505 interventions have introduced new selective pressures and contributed to population 506 turbulence. If so, these environmental conditions might select for fitter lineages that can 507 better establish persistence in hospital environments. Environmental persistence might also 508 be associated with a notable trade-off in virulence, as seen by the skew in isolates causing 509 clinical infections here. Under such conditions, IPC measures might have differential effects 510 at the strain level, and effective responses will require informed, dynamic IPC strategies. 511 Experimental characterisation of diverse CRAB lineages will be needed to assess their 512 variable ability to persist in hospital environments and ultimately infect patients. The GC2 513 cluster C25, which was persistent in this ICU and prominent amongst clinical isolates over 514 the course of this study (10/13; 76·9%), is an intriguing target for future laboratory studies 515 that might address these questions.

#### 516 **Acknowledgements**

517 This work was undertaken as part of the DETECTIVE research project funded by the 518 Medical Research Council (MR/S013660/1), and the National Natural Science Foundation of 519 China (U22A20338, 32270183, 81861138054, 32011530116). W.v.S was also supported by a 520 Wolfson Research Merit Award (WM160092). AM is also supported by the National Institute 521 for Health and Care Research (NIHR) Birmingham Biomedical Research Centre 522 (NIHR203326).

523

## 524 **References**



- 564 genotype-phenotype correlations in a collection of isolates. Antimicrob Agents 565 Chemother. 2019.
- 566 15. Lam MMC, Koong J, Holt KE, Hall RM, Hamidian M. Detection and typing of plasmids 567 in *Acinetobacter baumannii* using *rep* genes encoding replication initiation proteins. 568 Microbiol Spectr. 2023.
- 569 16. Croucher NJ, Page AJ, Connor TR, Delaney AJ, Keane JA, Bentley SD, et al. Rapid 570 phylogenetic analysis of large samples of recombinant bacterial whole genome 571 sequences using Gubbins. Nucleic Acids Res. 2015.
- 572 17. To TH, Jung M, Lycett S, Gascuel O. Fast dating using least-squares criteria and 573 algorithms. Syst Biol. 2016.
- 574 18. Minh BQ, Schmidt HA, Chernomor O, Schrempf D, Woodhams MD, von Haeseler A, et 575 al. IQ-TREE 2: New models and efficient methods for phylogenetic inference in the 576 genomic era. Mol Biol Evol. 2020.
- 577 19. Zhao F, Liu H, Yao Y, Zhang L, Zhou Z, Leptihn S, et al. Description of a rare 578 pyomelanin-producing carbapenem-resistant *Acinetobacter baumannii* strain 579 coharboring chromosomal OXA-23 and NDM-1. Microbiol Spectr. 2022.
- 580 20. Hansen F, Porsbo LJ, Frandsen TH, Kaygisiz ANS, Roer L, Henius AE, et al. 581 Characterisation of carbapenemase-producing *Acinetobacter baumannii* isolates from 582 Danish patients 2014-2021: detection of a new international clone - IC11. Int J 583 Antimicrob Agents. 2023.
- 584 21. Hua X, Moran RA, Xu Q, He J, Fang Y, Zhang L, et al. Acquisition of a genomic 585 resistance island (AbGRI5) from global clone 2 through homologous recombination in a 586 clinical *Acinetobacter baumannii* isolate. J Antimicrob Chemother. 2021.
- 587 22. Mann R, Rafei R, Gunawan C, Harmer CJ, Hamidian M. Variants of Tn*6924*, a novel Tn7 family transposon carrying the *bla*<sub>NDM</sub> metallo-β-lactamase and 14 copies of the *aphA6* amikacin resistance genes found in *Acinetobacter baumannii*. Microbiol Spect 589 *aphA6* amikacin resistance genes found in *Acinetobacter baumannii*. Microbiol Spectr. 590 2022.
- 591 23. Oldenkamp R, Schultsz C, Mancini E, Cappuccio A. Filling the gaps in the global 592 prevalence map of clinical antimicrobial resistance. Proc Natl Acad Sci USA. 2021.
- 593 24. Cong W, Cheng HY, Stuart B, Liu B, Tang Y, Wang Y, et al. Prevalence of antibiotic 594 prescribing in COVID-19 patients in China and other low- and middle-income countries 595 during the pandemic (December 2019-March 2021): a systematic review and meta-596 analysis. J Antimicrob Chemother. 2023.
- 597



599 **Figure 1: The ICU** *A. baumannii* **population.** A) Comparison of the *A. baumannii* 600 populations collected in this ICU over the initial (2019) and follow-up (2021) study periods. 601 Horizontal bars are proportional to the number of isolates of given sequence types (STs), 602 which are labelled and represented by different colours. Thinner horizontal lines and labels 603 indicate whether isolates were carbapenem-resistant (CRAB; red) or carbapenem-sensitive 604 (CSAB; blue). B) Overview of the spatiotemporal distribution of GC2/ST2 (blue) and ST164 605 (orange) isolates over the course of the 2021 study. Bed unit and room numbers are indicated 606 on the horizontal axis, and study week numbers on the vertical axis. The sizes of circles 607 correspond to the number of isolates collected from each patient/bed unit at each sampling 608 timepoint.

609



611 **Figure 2: The ICU GC2 population observed in this study.** A) Core-gene phylogeny (left) 612 and cluster characteristics (right). Reference genomes for clusters obtained in the 2019 study 613 are indicated by coloured circles at branch tips. Cluster designations from this study are 614 indicated by coloured boxes to the right of the phylogeny, along with boxes shaded as 615 outlined in the key to the left of the figure. B) Temporal distribution of GC2 clusters over the 616 course of this study. For each study week, columns are divided according to the numbers of 617 isolates of each GC2 cluster that were obtained, with colours corresponding to the key in part 618 A. C) Spatiotemporal distribution of transient GC2 clusters introduced by patients over the 619 course of this study. The meaning of shapes is outlined in the key below, and colours 620 correspond to those in the key in part A.



622 **Figure 3: Genomic characteristics of ST164** *A. baumannii***.** A) Schematic overview of the 623 genome of ST164 isolate DETAB-P462. The chromosome is shown as a large circle with the 624 locations of antibiotic resistance genes, MLST alleles, capsule (K) and outer core (OC) loci 625 indicated. To the right, plasmids pDETAB17-21 and their sizes are shown (not to scale). B) 626 Time-dated phylogeny of the ST164 population examined in this study. Prominent branch 627 dates are labelled, and the colours to the right of the phylogeny reflect ST164 clusters or the 628 presence of antibiotic resistance genes and plasmids as outlined in the key. The blue arrow 629 indicates the position of DETAB-R21, the reference isolated that was isolated in this ICU in 630 early 2021.



632 **Figure 4: Distribution of ST164 in the ICU.** A) Temporal distribution of ST164 clusters 633 over the course of this study. For each study week, columns are divided according to the 634 numbers of isolates of each ST164 cluster that were obtained, with colours corresponding to 635 the key. Spatiotemporal distribution of ST164 clusters isolated from patients (B) and the ICU 636 environment (C). Colours correspond to the key in part A, and the sizes of bubbles to the 637 numbers of isolates indicated by the key in part B.